19:34 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting production of PD-L1-loaded exosomes for prostate, colorectal cancers

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer; colorectal cancer Mouse studies suggest inhibiting RAB27A or SMPD3 alone or in combination with anti-PD-L1 antibodies could help treat prostate and colorectal cancers. In a mouse model of prostate...
22:35 , Apr 8, 2019 |  BC Extra  |  Preclinical News

Tumors release PD-L1 exosomes to evade antitumor immunity

UCSF researchers have found a clue to anti-PD-L1 resistance in exosomes released by tumors, and suggested blocking exosome release as a solution. In a Cell paper published Thursday, the University of California San Francisco team...
14:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

Blocking B cell vesicles to enhance chemotherapy

Blocking extracellular vesicles derived from B cells could offer a new therapeutic avenue to enhance the efficacy of chemotherapy for cancer, according to a Zhejiang University study. Chemotherapy reduces antitumor immunity by inducing systemic immunosuppression....
15:49 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample and mouse studies suggest inhibiting RAB27A-dependent formation of CD19-positive extracellular vesicles could enhance the efficacy of chemotherapy for colorectal cancer. In serum samples from colorectal cancer patients, levels of CD19-positive...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...